Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Six patients with autoimmune thrombocytopenic purpura (three of whom had CLL/NHL and one previous Hodgkin's disease) refractory to conventional therapy were treated with an antilymphocyte monoclonal antibody directed at CDw52 (CAMPATH-1). We observed response in four of the five evaluable patients; in three patients the response has lasted more than 4-9 months. However, response did not occur in most cases until 4-6 weeks after the commencement of the antibody therapy, suggesting that the mechanism of action is probably that of immune modulation.


Journal article


Br J Haematol

Publication Date





542 - 544


Adult, Antibodies, Monoclonal, Antigens, CD, Antigens, Neoplasm, CD52 Antigen, Female, Glycoproteins, Hodgkin Disease, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Male, Middle Aged, Platelet Count, Purpura, Thrombocytopenic, Idiopathic